FDA Mocra Cosmetics Compliance Services In The USA
A MoCRA compliance engagement should turn a defined U.S. cosmetics portfolio into an auditable launch decision—not merely a portal receipt. The workflow below shows what the consultant coordinates, what the manufacturer and label-named responsible person must supply, and which issues stop release.
This is a national U.S. FDA workflow. State rules, retailer specifications, and any drug obligations must be screened separately; outsourced work does not transfer statutory responsibility.
Gate 1 — classify the product and decide which obligations apply
Review the actual formula, use, all packaging and advertising claims, and sales channels before asking a laboratory or opening a listing. A moisturizer promoted to treat acne or bearing SPF claims may be a drug as well as a cosmetic; cosmetic listing does not replace drug compliance.
Identify the label-named responsible person and each manufacturing/processing facility. Check small-business status against the statutory criteria and excluded categories (including certain eye-mucous-membrane, injected, internal-use and long-lasting appearance products). The small-business exemption from registration/listing does not itself waive applicable cosmetic safety, labeling, safety-substantiation or adverse-event duties. The separate drug/device exemption under section 613 has a different scope.
Before treating a product as a MoCRA cosmetic-listing project, resolve the dual-use exclusion: under section 613, a cosmetic that is also a drug is outside section 607 cosmetic product listing; a facility manufacturing only such dual-use products is not registered under section 607 for those products. The applicable drug establishment and drug listing route still needs separate assessment. If the site also manufactures cosmetic-only products, review its cosmetic facility duties. For a claimed small-business exemption, verify the prior three-year average U.S. gross sales of cosmetics against the inflation-adjusted statutory threshold and check the excluded product categories; headcount or a small SKU portfolio alone is insufficient. A site that only labels, relabels, packages, repackages, stores or distributes cosmetics is outside the section 604 definition of a facility for registration purposes; filling the product into its container is not treated as packaging for this exclusion. Section 613 also exempts qualifying drug/device-regulated cosmetics from specified MoCRA duties beyond section 607, including sections 605 and 608; determine the applicable drug/device duties instead.
Intake file: six records that unblock execution
Request controlled, versioned documents, not verbal assurances. A consultant can compile the tracker, but each data owner must confirm its accuracy.
- Finished-product identity: SKU, label product name, intended use, consumer group, sales markets and launch date.
- Full qualitative/quantitative formula, ingredient identities, supplier specifications, color additives and fragrance/flavor status under confidentiality controls.
- Packaging artwork, instructions, online claims, warnings, net quantity, firm identification and functioning adverse-event contact channel.
- Factory map: legal operator, physical manufacturing/processing sites, FEI where available, contacts and any overseas U.S. agent details.
- Existing safety assessments, literature, microbiology/stability/compatibility data, batch records, complaints and proposed risk-based tests.
- Account ownership and permissions for FDA submissions, evidence of previous filings and renewal/update dates.
Six-stage delivery and hold-point map
The order is a practical project-control sequence, not a statutory FDA approval pathway.
| Stage | Handoff / tangible deliverable | Do not advance if |
|---|---|---|
| 1. Scope | Signed product-and-facility register; cosmetic/drug decision and exemption rationale | Claims or legal manufacturer are unresolved |
| 2. Gap | Requirements-and-evidence tracker with named owners, missing inputs and priorities | Formula or label version is uncontrolled |
| 3. Safety | Qualified safety review; targeted lab briefs, results, deviations and substantiation file | Material safety question has no support |
| 4. Artwork | Approved U.S. label text and live complaint intake channel; claims cross-check | Drug claim or material mislabeling remains |
| 5. Filing | Facility registration, where required, and product listing, where required; saved submissions/status | FEI/facility match, ingredient list or responsible person mismatch |
| 6. Release | Signed decision register, controlled dossier and calendar for post-launch duties | Any blocking item lacks documented closure |
Testing and evidence: order work by a documented risk question
For cosmetics covered by section 608, the responsible person generally must ensure and retain adequate safety substantiation. Section 608(b) provides a specific exception for compliant coal-tar hair dye, while still requiring safety-related records. FDA does not prescribe one universal cosmetic test package or require animal testing.
| Risk signal | Evidence or commissioned work | Decision point |
|---|---|---|
| Water-based product / contamination exposure | Review preservative, microbial quality and, where justified, challenge-test evidence | Escalate weak preservation or unexplained results |
| Skin contact, intended users or novel ingredient | Assess exposure, toxicology and relevant irritation/sensitization evidence; request targeted studies only for gaps | Qualified reviewer must support reasonable certainty of safety |
| Packaging, heat, transport or shelf life | Review stability/pack compatibility, batch data and claimed shelf life; test gaps where material | Resolve unstable formula or incompatible pack |
| Pigments, special ingredients or restricted substances | Check FDA color-additive use approvals and batch certification where applicable, plus restrictions | Stop a non-permitted use; testing does not legalize an ingredient |
Submission work: facility first where needed, then a consistent product listing
For a non-exempt manufacturing/processing facility, reconcile FEI, address, operator, brands, categories and responsible persons; arrange the U.S. agent information required for foreign-facility registration. Submit through Cosmetics Direct, another supported SPL route or FDA paper forms (Form 5066). Facility registration is renewed every two years, based on the initial registration date.
For non-exempt marketed cosmetics, the responsible person prepares product listing (Form 5067 or electronic equivalent): label product identity, category code, relevant facilities/FEI or exemption details, and ingredients. A listing may cover certain qualifying formula variants; do not assume every SKU needs an independent filing. Updates to listing information are provided annually. Capture a copy of the submitted dataset, reference/status and next review date. FDA issues no compliance certificate for registration or listing, and these steps are not product approval.
Statutory filing clocks versus project release gates
Do not confuse the consultant’s preferred pre-launch evidence review with the statutory submission clock. These are obligations under section 607, not steps in an FDA product-approval process. Apply them only after checking exemptions and the cosmetic-versus-drug route.
| Trigger / owner | Statutory clock | Practical handoff |
|---|---|---|
| New non-exempt manufacturing/processing facility — owner/operator | Register within 60 days after first beginning covered activity. | Confirm site identity and FEI; save facility submission/status. |
| Change to required facility-registration information — registrant | Amend within 60 days of the change. | Start a change ticket, reconcile FEI/site/brand/responsible-person fields and retain evidence. |
| Existing registered facility — owner/operator | Renew every two years from initial registration date. | Track the portal renewal date and the appropriate renewal method. |
| Cosmetic product first marketed after 29 December 2022 — label-named responsible person | List within 120 days after first marketing in interstate commerce; provide changes to listing information annually, including discontinuation. | Prepare product data ahead of launch when useful, but do not describe product listing as premarket FDA approval or an automatic pre-sale condition. |
For a cosmetic marketed as both a drug and a cosmetic, reassess the separate drug route instead of mechanically applying the cosmetic-only section 607 filing schedule. FDA charges no fee to submit section 607 facility registrations or product listings; consultancy, laboratory and translation costs are separate commercial charges.
Responsibility matrix: who owns each handoff
| Party | Accountability / evidence to return |
|---|---|
| Responsible person on label | Own safety substantiation, product listings where applicable, complaint/serious-event reporting and release decision; approve the dossier. |
| Manufacturer / processor | Confirm site and FEI facts, submit or authorize facility registration, supply process/batch/quality evidence and changes. |
| Laboratory / safety specialist | Specify method and sample identity, issue traceable results; professionally evaluate gaps without promising a mandated universal test. |
| Consultant / coordinator | Maintain master tracker, reconcile label–formula–facility–filing data, coordinate vendors and retain evidence/closeout; does not become FDA or automatically become the legal responsible person. |
The safety-substantiation, filing and serious-event duties above come from law. The project sign-off, stop/go register and vendor acceptance criteria are recommended delivery controls, not FDA-prescribed approvals.
Release gate: what the brand actually receives
Market readiness is a documented commercial decision by the responsible business, not an FDA clearance letter.
- Product-route memorandum with reasons for cosmetic-only, combined drug/cosmetic or other escalation.
- Version-controlled formula, safety-substantiation index, lab reports, deviations and reviewed final artwork.
- Facility and product submission copies or written, fact-specific exemption rationale; status checked, not presumed.
- Complaint intake SOP, serious adverse-event escalation owner and live channel on the label. For cosmetics subject to section 605: Serious events: report within 15 business days; qualifying follow-up information also has a 15-business-day deadline.
- Open-issues register showing owners and holds, formal sign-off, and a renewal/annual update and rule-change calendar.
After launch: trigger-based maintenance map
Operational change control prevents a clean launch file from becoming unreliable.
| Trigger | Immediate internal review | External consequence to check |
|---|---|---|
| New formula, pigment or fragrance | Reconcile safety, supplier evidence, ingredients, label and SKU grouping | Determine annual listing update and any new safety work; do not assume a new filing automatically |
| Different contract manufacturer or site | Confirm new facility status/FEI and manufacturing controls | Assess facility registration and listing facility identifiers; amend as applicable |
| Changed brand name, label firm or claims | Reassess classification, label contact, ownership and claim support | Check listing and label changes; drug route if therapeutic claims arise |
| Serious consumer complaint or safety signal | Triage immediately, preserve label and medical facts, investigate lot exposure | Determine mandatory FDA serious-adverse-event submission and possible broader action |
What to commission—and what no supplier can promise
Commission a deliverables-based scope: a gap report, evidence register, risk-based testing plan, accepted supplier reports, label/claim review, filing pack and a handover with change-control owners. Contractually specify who may access the portal, who signs submissions, which tests are conditional and how deficiencies are remediated. No standard FDA cosmetic “approval service” or universal laboratory certificate exists.
Separate the detailed U.S. label review into FDA labeling compliance services. For formula-specific classification and testing examples, use the U.S. face-cream compliance route. FDA’s GMP, fragrance-allergen and talc-testing rulemakings require status monitoring; a draft or withdrawn proposal must not be presented as an operative final rule.
Primary FDA sources
- MoCRA statutory overview
- Facility registration and listings
- Form 5066 — facility registration
- Form 5067 — product listing
- Safety and small businesses
- Serious adverse-event reporting
- FDA registration/listing guidance (timing and exclusions)
- Statutory facility definition (§ 604)
- Statutory drug/device overlap exception (§ 613)
- Safety substantiation and coal-tar dye exception (§ 608)
Execution-specific questions
Can a foreign company be the responsible person?
Potentially yes, if it is the manufacturer, packer or distributor named on the label under FDA’s definition. A foreign facility subject to registration must provide a U.S. agent; that agent is not automatically the label-named responsible person.
Does a small brand need a product listing?
Possibly not if the statutory small-business exemption applies, but exclusions depend on product type and relevant facts. Record the conclusion; do not treat “small” as a blanket safety or reporting waiver.
Which test is mandatory before Cosmetics Direct filing?
FDA has not imposed a single universal safety test. Review the formula, exposure and existing scientific evidence, then commission gap-specific work before responsible-person sign-off.
Does an FDA registration number or portal receipt authorize sales?
No. Registration and listing are not approvals, and FDA does not issue a compliance certificate. Safety, correct labeling and any other applicable legal requirements must be addressed separately.
What happens if the formula changes after launch?
Reopen the safety and labeling assessments, reconcile listing fields and the affected manufacturing sites, and determine applicable annual updates or other obligations. A changed formula does not by itself establish that every filing must be repeated.
Who responds to a serious adverse event?
For cosmetics subject to MoCRA section 605, the label-named responsible person has the FDA reporting duty: within 15 business days, with label copy; qualifying new medical information received within one year must also be submitted within 15 business days. The consultant may coordinate, not replace that duty.